Posted: February 14, 2014 at 9:41 am
Actualizacin de Baruc perro tratado con clulas madre, Costa Rica, dog treated with Stem Cells
Para ms informacin sobre los tratamientos con Clulas Madre, favor escribir al correo innovacelulasmadre@gmail.com o llamar al +(506) 88254973 Msica escog...
By: Priscilla Ortiz
See the article here:
Actualizacin de Baruc perro tratado con clulas madre, Costa Rica, dog treated with Stem Cells - Video
Posted: February 14, 2014 at 9:41 am
Stem Cells therapy - Age Reversal Study - Carmen
http://a1stemcells.com/anti-aging-2 Carmen #39;s testimonial recorded during her 7th injection. Stem cell rejuvenation program is taking place in Mexico If you w...
By: A1 Stem Cells
Read the rest here:
Stem Cells therapy - Age Reversal Study - Carmen - Video
Posted: February 14, 2014 at 9:41 am
What is Stem Cell Therapy?
According to J. Peter Rubin, MD, Chair of the University of Pittsburgh #39;s Department of Plastic Surgery, stem cells are small cells that live within the tissu...
By: Smart Beauty Guide
Read more:
What is Stem Cell Therapy? - Video
Posted: February 14, 2014 at 9:41 am
The Doctors TV Show: Stem Cell Treatment for Lichen Sclerosus
In a recent episode of "The Doctors", Jamie shared the tremendous pain and challenges she experienced with lichen sclerosus. The show also reveals how she wa...
By: Nathan Newman
See the rest here:
The Doctors TV Show: Stem Cell Treatment for Lichen Sclerosus - Video
Posted: February 14, 2014 at 9:41 am
Disgraced Korean scientist receives stem cell research patent
A former leading Korean geneticist has received a U.S patent on a controversial stem cell line that sparked a scandal nearly a decade ago. Hwang Woo-suk was ...
By: ARIRANG NEWS
Read more from the original source:
Disgraced Korean scientist receives stem cell research patent - Video
Posted: February 14, 2014 at 9:41 am
Biomedical Ethics of Stem Cell Research
February 12, 2014 Tulane University.
By: Rachel Thompson
Go here to read the rest:
Biomedical Ethics of Stem Cell Research - Video
Posted: February 14, 2014 at 9:41 am
Islam #39;s Position on human embryonic stem cell research by Sh. Yasir Birjas
877-Why-Islam presents Islam #39;s position on these unprecedented cases like human embryonic stem cell research? What are the rules to be followed when looking ...
By: 877-Why-Islam
See the original post:
Islam's Position on human embryonic stem cell research by Sh. Yasir Birjas - Video
Posted: February 14, 2014 at 5:52 am
Contact Information
Available for logged-in reporters only
Newswise Researchers at the University of California, San Diego School of Medicine have discovered that a well-known protein has a new function: It acts in a biological circuit to determine whether an immature neural cell remains in a stem-like state or proceeds to become a functional neuron.
The findings, published in the February 13 online issue of Cell Reports, more fully illuminate a fundamental but still poorly understood cellular act and may have significant implications for future development of new therapies for specific neurological disorders, including autism and schizophrenia.
Postdoctoral fellow Chih-Hong Lou, working with principal investigator Miles F. Wilkinson, PhD, professor in the Department of Reproductive Medicine and a member of the UC San Diego Institute for Genomic Medicine, and other colleagues, discovered that this critical biological decision is controlled by UPF1, a protein essential for the nonsense-mediated RNA decay (NMD) pathway.
NMD was previously established to have two broad roles. First, it is a quality control mechanism used by cells to eliminate faulty messenger RNA (mRNA) molecules that help transcribe genetic information into the construction of proteins essential to life. Second, it degrades a specific group of normal mRNAs. The latter function of NMD has been hypothesized to be physiologically important, but until now it had not been clear whether this is the case.
Wilkinson and colleagues discovered that in concert with a special class of RNAs called microRNA, UPF1 acts as a molecular switch to determine when immature (non-functional) neural cells differentiate into non-dividing (functional) neurons. Specifically, UPF1 triggers the decay of a particular mRNA that encodes for a protein in the TGF- signaling pathway that promotes neural differentiation. By degrading that mRNA, the encoded protein fails to be produced and neural differentiation is prevented. Thus, Lou and colleagues identified for the first time a molecular circuit in which NMD acts to drive a normal biological response.
NMD also promotes the decay of mRNAs encoding proliferation inhibitors, which Wilkinson said may explain why NMD stimulates the proliferative state characteristic of stem cells.
There are many potential clinical ramifications for these findings, Wilkinson said. One is that by promoting the stem-like state, NMD may be useful for reprogramming differentiated cells into stem cells more efficiently.
Another implication follows from the finding that NMD is vital to the normal development of the brain in diverse species, including humans. Humans with deficiencies in NMD have intellectual disability and often also have schizophrenia and autism. Therapies to enhance NMD in affected individuals could be useful in restoring the correct balance of stem cells and differentiated neurons and thereby help restore normal brain function.
Link:
Protein Switch Dictates Cellular Fate: Stem Cell or Neuron
Posted: February 14, 2014 at 5:52 am
Poway, California (PRWEB) February 13, 2014
The leading Regenerative Veterinary Medicine company, Vet-Stem, Inc., and Americas best-loved pet insurer, Petplan, are working together to bring stem cell therapy and other regenerative cell therapies to pets nationwide. Stem cell therapy by Vet-Stem has been available for pets like dogs and cats for the last decade and covered by Petplan since 2010.
Founded in 2003 by Chris and Natasha Ashton, Petplan was recently named to Forbes magazines annual ranking of Americas Most Promising Companies for the second year in a row, and is rated one of the top pet insurance companies by Consumer Advocate and Canine Journal. Petplan proudly offers life-long coverage for hereditary and chronic conditions as well as alternative treatments, like stem cell therapy, as standard.
Our core value is that pets come first, and that starts with our comprehensive plans. So, were excited to see so many of our policyholders start to take advantage of cutting-edge treatments like Vet-Stem Regenerative Cell Therapy. Our team thrives on being able to provide coverage for the best and most up-to-date treatment modalities for the pets in our Petplan family, so hearing great stories about stem cell therapy from our policyholders is a real boost for us! - Dr. Jules Benson, Vice President of Veterinary Services at Petplan
Current uses of stem cell therapy are treating the pain and inflammation from arthritis and to repair orthopedic injuries. According to veterinarians, greater than 80% of dogs showed an improved quality of life after stem cell therapy. At 90 days post-treatment, more than 33% of dogs discontinued use of non-steroidal anti-inflammatory drugs (NSAIDs) completely, with an additional 28% decreasing their usage.
I started Vet-Stem in order to help horses with career-ending injuries to their tendons and ligaments, but so many more animals have been saved from a life of pain or even from euthanasia. I feel privileged and excited to be a part of this therapy that has changed how veterinary medicine is practiced, as well as contributing to changes in human medicine, - Robert Harman, DVM, CEO, Vet-Stem, Inc.
About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.
Follow this link:
Vet-Stem, Inc. and Petplan Work Together in the New Year to Bring Regenerative Cell Therapies to Pets
Posted: February 14, 2014 at 5:52 am
;
Dr. John Dick, a senior scientist at Princess Margaret Cancer Centre in Toronto, is shown in a handout photo.
TORONTO Canadian researchers have discovered a pre-leukemic stem cell that may be at the root of acute myeloid leukemia and also be the bad actor that evades chemotherapy and triggers a relapse in patients who have gone into remission.
Acute myeloid leukemia, or AML, is a rapidly progressing cancer of the blood and bone marrow that affects myeloid cells, which normally develop into mature red and white blood cells and platelets.
Leukemia develops when blood stem cells in the bone marrow make abnormal blood cells, which over time crowd out normal blood cells, affecting their ability to function as they should.
READ MORE:Could this new therapy kill cancer? Canadian doc thinks so
In a paper published online Wednesday in the journal Nature, researchers led by John Dick of Princess Margaret Cancer Centre in Toronto report on the discovery of a pre-leukemic stem cell the forerunner to leukemia stem cells that give rise to the disease.
A leukemia stem cell can lie dormant and theyre the ones that will sustain the growth of the leukemia, Dick said in an interview. The pre-leukemic guys are basically the ancestors that are on their way to becoming leukemia and becoming leukemic stem cells.
Dicks lab was the first to identify the existence of leukemia stem cells, in 1994, followed by the discovery of colon cancer stem cells in 2007.
Teasing out pre-leukemic stem cells from the blood of AML patients based on samples taken at diagnosis, after chemotherapy-induced remission, and then following recurrence advances the understanding of the genetic changes a normal cell has to go through before it turns into AML.
More:
Scientists discover pre-leukemic stem cell at root of cancer
